Zobrazeno 1 - 10
of 318
pro vyhledávání: '"Fumio, Imamura"'
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimer
Externí odkaz:
https://doaj.org/article/44b83896764b4d85bc01ecb3c4630dd4
Autor:
Kei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, Tomoyuki Yamasaki, Keiichiro Honma, Shigenori Nagata, Yoji Kukita, Fumie Fujisawa, Tazuko Inoue, Yuko Yamaguchi, Mitsuko Kitasaka, Toru Wakamatsu, Takuo Yamai, Sachiko Yamamoto, Takuji Hayashi, Takako Inoue, Motohiro Tamiya, Fumio Imamura, Kazuo Nishimura, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 2970-2977 (2022)
Abstract Background The usefulness of comprehensive genomic profiling (CGP) panels for thoracic malignancies after completion of the standard treatment is unclear. Methods The results of CGP panels for malignant thoracic diseases performed at our hos
Externí odkaz:
https://doaj.org/article/5cced9d17ae34c29aad0192b84e309a7
Autor:
Kei Kunimasa, Kazumi Nishino, Yoshiharu Sato, Masahide Mori, Shoichi Ihara, Hidekazu Suzuki, Izumi Nagatomo, Toru Kumagai, Toshitaka Morishima, Fumio Imamura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer
Externí odkaz:
https://doaj.org/article/d8b2c1c79b144483bd271dabdd44fdc3
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/9ac77df433144c60bb72e35db443b3df
Autor:
Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, Yoshihiko Taniguchi, Kazumi Nishino, Shinji Atagi, Tomonori Hirashima, Fumio Imamura, Toru Kumagai, Hidekazu Suzuki
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa gro
Externí odkaz:
https://doaj.org/article/971c6d6d531f455c899f4cb3858135b3
Autor:
Masahiko Higashiyama, Ryohei Miyazaki, Hiroshi Yamamoto, Takashi Anayama, Shinya Kikuchi, Kentaro Hirohashi, Jiro Okami, Tomohiro Maniwa, Toru Kimura, Kazumasa Orihashi, Fumio Imamura
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background AminoIndex™ Cancer Screening (AICS (lung)) was developed as a screening test for lung cancer using a multivariate analysis of plasma-free amino acid (PFAA) profiles. According to the developed index composed of PFAA, the probabi
Externí odkaz:
https://doaj.org/article/df564f01820f418ba1ba87f80390286c
Autor:
Kei Kunimasa, Yosuke Hirotsu, Kenji Amemiya, Yuki Nagakubo, Taichiro Goto, Yoshihiro Miyashita, Yumiko Kakizaki, Toshiharu Tsutsui, Sotaro Otake, Hiroaki Kobayashi, Rumi Higuchi, Kie Inomata, Takashi Kumagai, Hitoshi Mochizuki, Harumi Nakamura, Shin‐ichi Nakatsuka, Kazumi Nishino, Fumio Imamura, Toru Kumagai, Toshio Oyama, Masao Omata
Publikováno v:
Cancer Medicine, Vol 9, Iss 13, Pp 4501-4511 (2020)
Abstract Introductions When tumor tissue samples are unavailable to search for actionable driver mutations, archival cytology samples can be useful. We investigate whether archival cytology samples can yield reliable genomic information compared to c
Externí odkaz:
https://doaj.org/article/75f0fcd978ad4f3bae7726af3c2c4b63
Autor:
Kei Kunimasa, MD, PhD, Risa Kamada, MD, Toru Oka, MD, PhD, Makiko Oboshi, MD, PhD, Madoka Kimura, MD, Takako Inoue, MD, Motohiro Tamiya, MD, Tatsuya Nishikawa, MD, PhD, Taku Yasui, MD, PhD, Wataru Shioyama, MD, PhD, Kazumi Nishino, MD, PhD, Fumio Imamura, MD, PhD, Toru Kumagai, MD, PhD, Masashi Fujita, MD, PhD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 1, Pp 1-10 (2020)
Objectives: The purpose of this study was to assess osimertinib-associated cardiac adverse events (AEs) in a real-world setting, using a retrospective single-center cohort study in Japan. Background: Cases of osimertinib-associated cardiac AEs have b
Externí odkaz:
https://doaj.org/article/cd084dc47bf644bfa229ea9866542e66
Autor:
Nahomi Tokudome, Yasuhiro Koh, Hiroaki Akamatsu, Daichi Fujimoto, Isamu Okamoto, Kazuhiko Nakagawa, Toyoaki Hida, Fumio Imamura, Satoshi Morita, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Epidermal growth factor receptor (EGFR)-sensitizing mutation, exon 19 deletion consists of several molecular variants. Influences of these variants on clinical response to EGFR tyrosine kinase inhibitors remain elusive. Methods We
Externí odkaz:
https://doaj.org/article/b60fdaae47f44203886f8b43ab41f084
Autor:
Yoshihiro Hattori, Yuko Kono, Shoichi Itoh, Takako Inoue, Yoshiko Urata, Yoshitaka Kawa, Rie Tohnai, Toru Kumagai, Kazumi Nishino, Ryuji Uozumi, Satoshi Morita, Shunichi Negoro, Fumio Imamura, Miyako Satouchi
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The aim of this study was to evaluate the efficacy and safety of nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). Methods Chemotherapy-naïve patients with advanced NS
Externí odkaz:
https://doaj.org/article/888a7fee177744729ec42d5d2ad1be86